Johnson and Johnson: Tremfya is the First and Only IL-23 Inhibitor to Demonstrate Robust Results With a Fully Subcutaneous Regimen in Both Induction and Maintenance in Crohn's Disease
October 29, 2024
October 29, 2024
NEW BRUNSWICK, New Jersey, Oct. 29 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
A greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo
TREMFYA could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pen . . .
* * *
A greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo
TREMFYA could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pen . . .